Limitations of medical therapy in patients with pure coronary spastic angina

Shozo Sueda1, Hiroaki Kohno, Hiroshi Fukuda

  • 1Department of Cardiology, Saiseikai Saijo Hospital, Saijo City, Japan.

Chest
|February 11, 2003
PubMed

Insights

Long-acting calcium antagonists were effective for pure coronary spastic angina in only 38% of patients. Medical therapy limitations were noted in 42%, particularly for those with diffuse spasms or a longer history of chest pain.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Pure coronary spastic angina (PCSA) is a condition characterized by chest pain due to coronary artery spasms.
  • Effective long-term management strategies for PCSA remain an area of clinical interest.

Purpose of the Study:

  • To evaluate the efficacy of medical treatment, specifically long-acting calcium antagonists, for patients diagnosed with pure coronary spastic angina.

Main Methods:

  • A cohort of 71 consecutive patients with PCSA, confirmed by coronary arteriography, were studied over a minimum 2-year follow-up period.
  • Patients received treatment with long-acting calcium antagonists.
  • Response to treatment was assessed by the disappearance or persistence of chest pain attacks.

Main Results:

  • Medical treatment with long-acting calcium antagonists was effective in 38% of patients (27 out of 71).
  • A significant proportion of patients (62%) continued to experience chest pain attacks despite treatment.
  • Positive treatment responses were observed in female patients and those with ST-segment elevation during spasm provocation tests.
  • Poor responses were associated with a longer history of chest pain and diffuse coronary spasms.

Conclusions:

  • Long-acting calcium antagonists demonstrate limited efficacy in a substantial portion (42%) of patients with pure coronary spastic angina.
  • Treatment effectiveness varied based on patient demographics and specific diagnostic findings.
  • Further research may be needed to optimize therapeutic strategies for PCSA.
Abstract

Related Concept Videos

Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina II: Classification01:27

Angina II: Classification

Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...